Filing Details
- Accession Number:
- 0001140361-18-012009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-05 16:56:22
- Reporting Period:
- 2018-03-01
- Accepted Time:
- 2018-03-05 16:56:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501989 | Cytomx Therapeutics Inc. | CTMX | Pharmaceutical Preparations (2834) | 273521219 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706863 | Debanjan Ray | C/O Cytomx Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco CA 94080 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-01 | 13,000 | $1.26 | 17,741 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-01 | 13,000 | $29.40 | 4,741 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-03-02 | 5,515 | $1.26 | 10,256 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-02 | 5,515 | $30.06 | 4,741 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-03-02 | 14,485 | $1.13 | 19,226 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-02 | 12,541 | $30.41 | 6,685 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-02 | 1,944 | $31.02 | 4,741 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-01 | 13,000 | $0.00 | 13,000 | $1.26 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-02 | 5,515 | $0.00 | 5,515 | $1.26 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-02 | 14,485 | $0.00 | 14,485 | $1.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 20,225 | 2023-12-10 | No | 4 | M | Direct | |
| 14,710 | 2023-12-10 | No | 4 | M | Direct | |
| 20,000 | 2021-09-13 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.38, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
